True Nature Converts Bridge Notes into Series A Preferred Stock and Secures Additional Funding

On January 20, 2025, True Nature (OTCMKTS:TNTY) reported a significant financial development through a Form 8-K filing with the United States Securities and Exchange Commission. The company announced the conversion of its FY2024 Bridge Notes into Series A Preferred Stock. This conversion was valued at $580,132 and resulted in the issuance of 23.205 shares of Series A Preferred Stock to three institutional investors. The Series A Shares have the option to be converted into common stock based on a specified conversion price.

Moreover, True Nature disclosed that it has secured additional funding by selling 4,000 shares of the Series A Preferred Stock, amounting to $100,000. The company noted its intention to register the underlying common stock for resale, thereby potentially introducing new equity into the market.

The 8-K filing indicated that the issuance of preferred stock to accredited investors was conducted in a manner not involving a public offering, in adherence to Section 4(a)(2) of the United States Securities Act of 1933. Notably, the securities issued have not been registered and are subject to certain restrictions on trading within the United States unless appropriate exemptions are met.

The company’s forward-looking statements in the filing highlighted the risks and uncertainties associated with the planned redemption of the Series A Preferred Stock. True Nature stressed that while efforts would be made to register the resale of common stock issued in exchange for obligations, there could be delays in the regulatory process or challenges in creating a market for the stock.

Financial statements and exhibits attached to the filing provided detailed information on the Certificate of Designation for Series A Amortizing Convertible Preferred Stock, the Form of Obligation Exchange Agreement for 2024 Bridge Notes, and the Form of Series A Preferred Stock subscription agreement. These documents shed light on the terms and conditions governing the conversion and issuance of preferred stock.

True Nature’s proactive measures to convert debt instruments into equity and secure additional funding represent strategic maneuvers aimed at bolstering its financial position. The company’s focus on regulatory compliance and transparency in its financial dealings underscores its commitment to sustainable growth and shareholder value.

The financial landscape for True Nature is poised for potential growth as it navigates the complexities of capital restructuring and equity financing in the competitive market environment. Investors and stakeholders will be keen on monitoring the company’s progress in executing its financial strategies and exploring opportunities for value creation in the evolving market dynamics.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read True Nature’s 8K filing here.

About True Nature

True Nature Holding, Inc focuses on engaging in compounding pharmacy activities direct to consumers, doctors, and veterinary professionals. It also focuses on the development of software applications in the healthcare arena, including telemedicine; and consideration of services offering using blockchain encryption technology for various aspects of the healthcare industry.